Astrazeneca (AZN) closed at $96.34 within the newest buying and selling session, marking a +1.94% transfer from the prior day. The inventory outperformed the S&P 500, which registered a each day lack of 0.53%. In the meantime, the Dow skilled a drop of 0.09%, and the technology-dominated Nasdaq noticed a lower of 1%.
Coming into at the moment, shares of the pharmaceutical had gained 3.46% up to now month. In that very same time, the Medical sector gained 0.09%, whereas the S&P 500 gained 2.06%.
Traders shall be eagerly looking forward to the efficiency of Astrazeneca in its upcoming earnings disclosure. The corporate’s earnings report is ready to be unveiled on February 10, 2026. The corporate’s upcoming EPS is projected at $1.09, signifying a 3.81% enhance in comparison with the identical quarter of the earlier yr. In the meantime, the Zacks Consensus Estimate for income is projecting web gross sales of $15.76 billion, up 5.81% from the year-ago interval.
When it comes to your entire fiscal yr, the Zacks Consensus Estimates predict earnings of $4.59 per share and a income of $58.73 billion, indicating modifications of +11.68% and 0%, respectively, from the previous yr.
Traders also needs to word any current modifications to analyst estimates for Astrazeneca. Such current modifications normally signify the altering panorama of near-term enterprise traits. Consequently, upward revisions in estimates categorical analysts’ positivity in direction of the enterprise operations and its means to generate earnings.
Our analysis demonstrates that these changes in estimates straight affiliate with imminent inventory worth efficiency. To benefit from this, we have established the Zacks Rank, an unique mannequin that considers these estimated modifications and delivers an operational score system.
The Zacks Rank system, which ranges from #1 (Sturdy Purchase) to #5 (Sturdy Promote), has a powerful outside-audited monitor document of outperformance, with #1 shares producing a median annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% greater throughout the previous month. Astrazeneca is holding a Zacks Rank of #3 (Maintain) proper now.
Digging into valuation, Astrazeneca at present has a Ahead P/E ratio of 18.33. This signifies a reduction compared to the common Ahead P/E of 20.82 for its trade.
Traders also needs to word that AZN has a PEG ratio of 1.56 proper now. The PEG ratio is akin to the generally utilized P/E ratio, however this measure additionally incorporates the corporate’s anticipated earnings development charge. As of the shut of commerce yesterday, the Medical – Biomedical and Genetics trade held a median PEG ratio of 1.49.
The Medical – Biomedical and Genetics trade is a part of the Medical sector. With its present Zacks Trade Rank of 96, this trade ranks within the prime 40% of all industries, numbering over 250.
The Zacks Trade Rank assesses the energy of our separate trade teams by calculating the common Zacks Rank of the person shares contained throughout the teams. Our analysis exhibits that the highest 50% rated industries outperform the underside half by an element of two to 1.
Do not forget to make use of Zacks.com to maintain monitor of all these stock-moving metrics, and others, within the upcoming buying and selling classes.
Simply Launched: Zacks High 10 Shares for 2026
Hurry – you may nonetheless get in early on our 10 prime tickers for 2026. Handpicked by Zacks Director of Analysis Sheraz Mian, this portfolio has been stunningly and constantly profitable.
From inception in 2012 by November, 2025, the Zacks High 10 Shares gained +2,530.8%, greater than QUADRUPLING the S&P 500’s +570.3%.
Sheraz has combed by 4,400 firms coated by the Zacks Rank and handpicked the most effective 10 to purchase and maintain in 2026. You may nonetheless be among the many first to see these just-released shares with huge potential.
AstraZeneca PLC (AZN) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
